HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
-23.72%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$2.33B
AUM Growth
+$2.33B
(-16%)
Cap. Flow
+$76.2M
Cap. Flow
% of AUM
3.28%
Top 10 Holdings %
Top 10 Hldgs %
52.39%
Holding
72
New
16
Increased
17
Reduced
10
Closed
23
Top Buys
| 1 |
Encompass Health
EHC
|
$97.7M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
$94.2M |
| 3 |
Haemonetics
HAE
|
$89.6M |
| 4 |
CVS Health
CVS
|
$73.2M |
| 5 |
Welltower
WELL
|
$72.4M |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
$140M |
| 2 |
Johnson & Johnson
JNJ
|
$100M |
| 3 |
Hologic
HOLX
|
$64.5M |
| 4 |
XENT
Intersect ENT, Inc
XENT
|
$63.2M |
| 5 |
Danaher
DHR
|
$50.5M |
Sector Composition
| 1 | Healthcare | 93.12% |
| 2 | Real Estate | 5.44% |
| 3 | Industrials | 0% |
| 4 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Pacira BioSciences
PCRX
$1.2B
| $29.8M | 1.27% | 887,370 +116,230 | +15% | +$3.9M |
|
|
BLUE
27
DELISTED
bluebird bio
BLUE
| $28.6M | 1.22% | 622,210 -58,220 | -9% | -$2.68M |
|
|
HZNP
28
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $23.5M | 1.01% | +794,480 | New | +$23.5M |
|
29
Becton Dickinson
BDX
$55.3B
| $23M | 0.98% | 100,000 -116,000 | -54% | -$26.7M |
|
|
30
Hologic
HOLX
$14.9B
| $21.9M | 0.94% | 625,240 -1,838,800 | -75% | -$64.5M |
|
31
HCA Healthcare
HCA
$94.5B
| $20.6M | 0.88% | 229,730 -506,940 | -69% | -$45.5M |
|
|
BMY.RT
32
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $18.3M | 0.78% | 4,825,260 +1,683,419 | +54% | +$6.4M |
|
|
ARNA
33
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $18.3M | 0.78% | +436,340 | New | +$18.3M |
|
34
Thermo Fisher Scientific
TMO
$186B
| $17M | 0.73% | +60,000 | New | +$17M |
|
35
SPDR S&P Biotech ETF
XBI
$5.07B
| $15.2M | 0.65% | +196,850 | New | +$15.2M |
|
36
Biogen
BIIB
$19.4B
| $15.2M | 0.65% | +48,002 | New | +$15.2M |
|
37
Zymeworks
ZYME
$1.12B
| $14.8M | 0.63% | +416,700 | New | +$14.8M |
|
38
Agios Pharmaceuticals
AGIO
$2.19B
| $14.5M | 0.62% | 408,844 -288,546 | -41% | -$10.2M |
|
39
Teva Pharmaceuticals
TEVA
$21.1B
| $13.4M | 0.57% | +1,492,800 | New | +$13.4M |
|
|
ALXN
40
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $13.3M | 0.57% | +148,270 | New | +$13.3M |
|
41
Envista
NVST
$3.52B
| $13.3M | 0.57% | 888,210 -1,957,940 | -69% | -$29.3M |
|
42
Bristol-Myers Squibb
BMY
$96B
| $9.72M | 0.42% | 174,360 -665,640 | -79% | -$37.1M |
|
43
Rocket Pharmaceuticals
RCKT
$354M
| $5.16M | 0.22% | 369,639 -18,721 | -5% | -$261K |
|
|
SRGA
44
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $3.69M | 0.16% | 2,158,644 | – | – |
|
|
PTE
45
DELISTED
PolarityTE, Inc. Common Stock
PTE
| $687K | 0.03% | 636,110 | – | – |
|
46
Axsome Therapeutics
AXSM
$6.05B
| – | – | -408,617 | Closed | -$42.2M |
|
47
Cigna
CI
$80.3B
| – | – | -168,730 | Closed | -$34.5M |
|
48
Centene
CNC
$14.3B
| – | – | -560,900 | Closed | -$35.3M |
|
|
49
Danaher
DHR
$147B
| – | – | -328,970 | Closed | -$50.5M |
|
50
Edwards Lifesciences
EW
$47.8B
| – | – | -133,210 | Closed | -$31.1M |
|